The upside of being a digital pharma player
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
We investigated the state of artificial intelligence (AI) in pharmaceutical research and development (R&D) and outline here a risk and reward perspective regarding digital R&D. Given the novelty of the research area, a combined qualitative and quantitative research method was chosen, including the analysis of annual company reports, investor relations information, patent applications, and scientific publications of 21 pharmaceutical companies for the years 2014 to 2019. As a result, we can confirm that the industry is in an 'early mature' phase of using AI in R&D. Furthermore, we can demonstrate that, despite the efforts that need to be managed, recent developments in the industry indicate that it is worthwhile to invest to become a 'digital pharma player'.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Deep learning enables rapid identification of potent DDR1 kinase inhibitors
Zhavoronkov, A., Ivanenkov, Y. A., Aliper, A., Veselov, M. S., Aladinskiy, V. A., Aladinskaya, A. V., Terentiev, V. A., Polykovskiy, D. A., Kuznetsov, M. D., Asadulaev, A., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0224-x · Cited by 1,573
Impact of high-throughput screening in biomedical research
Macarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., Green, D. V. S., Hertzberg, R. P., Janzen, W. P., Paslay, J. W., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3368 · Cited by 1,364
A clinically applicable approach to continuous prediction of future acute kidney injury
Tomašev, N., Glorot, X., Rae, J. W., Zielinski, M., Askham, H., Saraiva, A., Mottram, A., Meyer, C., Ravuri, S., Protsyuk, I., et al. (2019) · Nature · doi:10.1038/s41586-019-1390-1 · Cited by 1,086
Artificial intelligence for clinical trial design
Harrer, S., Shah, P., Antony, B., & Hu, J. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.05.005 · Cited by 672
Artificial intelligence for aging and longevity research: Recent advances and perspectives
Zhavoronkov, A., Mamoshina, P., Vanhaelen, Q., Scheibye-Knudsen, M., Moskalev, A., & Aliper, A. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2018.11.003 · Cited by 246
Predicting responses to platin chemotherapy agents with biochemically-inspired machine learning
Mucaki, E. J., Zhao, J. Z. L., Lizotte, D. J., & Rogan, P. K. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-018-0034-5 · Cited by 200
Predicting the early risk of chronic kidney disease in patients with diabetes using real-world data
Ravizza, S., Huschto, T., Adamov, A., Böhm, L., Büsser, A., Flöther, F. F., Hinzmann, R., König, H., McAhren, S. M., Robertson, D. H., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0239-8 · Cited by 167
Weng, S. F., Vaz, L., Qureshi, N., & Kai, J. (2019) · PLOS ONE · doi:10.1371/journal.pone.0214365 · Cited by 118
Improved Classification of Blood-Brain-Barrier Drugs Using Deep Learning
Miao, R., Xia, L.-Y., Chen, H.-H., Huang, H.-H., & Liang, Y. (2019) · Scientific Reports · doi:10.1038/s41598-019-44773-4 · Cited by 91
Cited by
Artificial intelligence and innovation management: A review, framework, and research agenda✰
Haefner, N., Wincent, J., Parida, V., & Gassmann, O. (2021) · Technological Forecasting and Social Change · doi:10.1016/j.techfore.2020.120392 · Cited by 1,073
Self-citationThe role of artificial intelligence in business transformation: A case of pharmaceutical companies
Kulkov, I. (2021) · Technology in Society · doi:10.1016/j.techsoc.2021.101629 · Cited by 188
Repurposing drugs to treat cardiovascular disease in the era of precision medicine
Abdelsayed, M., Kort, E. J., Jovinge, S., & Mercola, M. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00717-6 · Cited by 93
“Increasing attention is being given to the use of machine learning to define signatures of disease 105 .”
BackgroundToward the institutionalization of quantum computing in pharmaceutical research
Zinner, M., Dahlhausen, F., Boehme, P., Ehlers, J., Bieske, L., & Fehring, L. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2021.10.006 · Cited by 43
Metadata
- Authors
- Schuhmacher, A., Gatto, A., Hinder, M., Kuss, M., & Gassmann, O.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 25
- Issue
- 9
- Pages
- 1569-1574
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W3035030180
- Cited by
- 62
- References
- 9
- FWCI
- 5.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The upside of being a digital pharma player. https://app.cochat.ai/papers/10.1016/j.drudis.2020.06.002
- The paper
- Schuhmacher, A., Gatto, A., Hinder, M., Kuss, M., & Gassmann, O. (2020). The upside of being a digital pharma player. Drug Discovery Today. https://doi.org/10.1016/j.drudis.2020.06.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.